Opinion|Videos|January 19, 2026
Additional SUMMIT Data for Bezuclastinib in Non-Advanced Systemic Mastocytosis
Author(s)Lindsay Rein, MD, Frederick Lansigan, MD
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional findings from the SUMMIT trial from ASH 2025 for bezuclastinib in non-advanced systemic mastocytosis.
Advertisement
Episodes in this series
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional SUMMIT trial data presented at ASH 2025, expanding on the clinical activity of bezuclastinib (CGT9486) in non-advanced systemic mastocytosis. They examine durability of response, patient-reported outcomes, and longer-term safety observations. Rein and Lansigan consider how these results further clarify the potential role of bezuclastinib in disease management.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5